StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Quarterly ResultMay 13, 2026, 04:18 PM

Dyadic International Q1 Revenue +182% to $1.11M; Net Loss $(1.95)M

AI Summary

Dyadic International reported a significant increase in total revenue for Q1 2026, reaching $1.11 million, up 182.2% year-over-year, driven by growth in research, grant, and new license revenue. The company also reduced its net loss to $(1.95) million from $(2.03) million in the prior year. Despite improved operational results, the company's total stockholders' equity turned negative, and it continues to anticipate losses and negative cash flows, relying on existing capital and future financing to meet its operational needs.

Key Highlights

  • Total revenue increased 182.2% to $1.11 million for Q1 2026, up from $393,572 in Q1 2025.
  • Net loss decreased to $(1.95) million, or $(0.05) per share, for Q1 2026, from $(2.03) million in Q1 2025.
  • License and milestone revenue was $220,000 in Q1 2026, compared to $0 in the prior year period.
  • Cash, cash equivalents, and restricted cash totaled $5.16 million as of March 31, 2026.
  • Total stockholders' equity was $(407,732) as of March 31, 2026, down from $1.23 million at December 31, 2025.
  • Net cash used in operating activities was $(1.96) million for the three months ended March 31, 2026.
  • The company expects its $6.6 million in existing capital to meet liquidity requirements for at least 12 months.
  • An At-The-Market Equity Offering Program for up to $4.24 million was established in March 2026.